Theravance Biopharma (NASDAQ:TBPH) Major Shareholder Eli Samaha Sells 273,871 Shares of Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) major shareholder Eli Samaha sold 273,871 shares of the business’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $17.23, for a total transaction of $4,718,797.33. Following the completion of the sale, the insider owned 9,237,279 shares in the company, valued at approximately $159,158,317.17. This trade represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Eli Samaha also recently made the following trade(s):

• On Wednesday, July 1st, Eli Samaha sold 37,799 shares of Theravance Biopharma stock. The shares were sold at an average price of $17.00, for a total value of $642,583.00.
• On Tuesday, June 30th, Eli Samaha sold 25,027 shares of Theravance Biopharma stock. The stock was sold at an average price of $17.13, for a total value of $428,712.51.

Theravance Biopharma Stock Performance

TBPH stock traded down $0.02 during mid-day trading on Wednesday, reaching $16.98. 1,319,960 shares of the stock traded hands, compared to its average volume of 689,283. Theravance Biopharma, Inc. has a one year low of $10.82 and a one year high of $21.03. The stock has a market capitalization of $875.32 million, a PE ratio of 7.72 and a beta of 0.17. The business has a 50-day moving average price of $16.56 and a two-hundred day moving average price of $17.29.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%.The business had revenue of $17.70 million for the quarter. On average, equities analysts expect that Theravance Biopharma, Inc. will post 1.54 earnings per share for the current fiscal year.

Institutional Trading of Theravance Biopharma

A number of hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in Theravance Biopharma by 2.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company’s stock worth $32,289,000 after purchasing an additional 54,152 shares during the last quarter. State Street Corp raised its holdings in shares of Theravance Biopharma by 4.4% during the fourth quarter. State Street Corp now owns 1,101,892 shares of the biopharmaceutical company’s stock worth $20,616,000 after purchasing an additional 45,987 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Theravance Biopharma by 14.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 983,615 shares of the biopharmaceutical company’s stock worth $15,960,000 after purchasing an additional 124,658 shares during the period. Geode Capital Management LLC raised its stake in shares of Theravance Biopharma by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 938,724 shares of the biopharmaceutical company’s stock valued at $17,567,000 after buying an additional 40,734 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in shares of Theravance Biopharma in the third quarter worth about $10,611,000. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on TBPH. Oppenheimer lowered Theravance Biopharma from an “outperform” rating to a “market perform” rating in a report on Thursday, March 5th. Zacks Research lowered Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 8th. TD Cowen upped their target price on Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a report on Monday, March 23rd. Wall Street Zen downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings lowered Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 27th. One analyst has rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $21.40.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.